Exagen Inc. to Participate in December Investor Conferences

Rhea-AI Summary

Exagen Inc. (Nasdaq: XGN) announced its participation in key December investor conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference will feature a recorded company presentation available from November 23 to December 3, 2020. Additionally, Ron Rocca, the President and CEO, will engage in a Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 2, 2020, at 10:30 am EST. Exagen focuses on advancing care for patients with autoimmune diseases, utilizing its innovative AVISE® testing products.

SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following December investor conferences:

• Piper Sandler 32^nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020
  A recorded company presentation will be available via the Piper Sandler conference site from November 23 to December 3, and on the Exagen website at: https://investors.exagen.com/events

• Evercore ISI 3^rd Annual HealthCONx Conference, December 1-3, 2020
  Exagen President and CEO Ron Rocca will participate in a Fireside Chat on Wednesday, December 2, 2020, at 10:30 am EST. A link to the live webcast of the Fireside Chat will be posted to the Exagen website at: https://investors.exagen.com/events

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients.  For more information, please visit www.Exagen.com.

Investors
Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com 
646.677.1838

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514

FAQ

What conferences will Exagen Inc. participate in for December 2020?

Exagen Inc. will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, and the Evercore ISI 3rd Annual HealthCONx Conference from December 1-3, 2020.

When is Exagen's Fireside Chat scheduled during the Evercore ISI conference?

Exagen's Fireside Chat, featuring President and CEO Ron Rocca, is scheduled for December 2, 2020, at 10:30 am EST.

Where can I access the recorded presentation from Exagen at the Piper Sandler conference?

The recorded presentation will be available on the Piper Sandler conference site from November 23 to December 3, 2020, as well as on Exagen's website.

What is the focus of Exagen's testing products?

Exagen's testing products focus on transforming care for patients with autoimmune diseases by aiding differential diagnosis and optimizing therapeutic intervention.